30 ml of tirzepatide Tirzepatide - 30mg

Lower dose semaglutide (0.1, 0.2 and 0.4 mg) improved non-alcoholic steatohepatitis (NASH) in another trial (mean age 55.9 years, but the inclusion of older adults up to 75 years)

Strategic testing of initial orders from new vendors or periodic verification of ongoing suppliers balances cost against verification value

Encouraged to aim for metoprolol dose of at least 100mg or bisoprolol dose of at least 5mg Primary endpoint: Composite of death from any cause or new myocardial infarction Secondary endpoints: death from any cause death from cardiovascular causes myocardial infarction hospitalization for atrial fibrillation hospitalization for heart failure Results: Population: Median age: 65 years 22.5% of the patients were women 35.2% had an ST-segment elevation myocardial infarction Beta-blocker group: 2508 patients w 1560 (62.2%) treated with metoprolol 948 (37.8%) treated with bisoprolol Median follow-up: 3.5 years (interquartile range, 2.2 to 4.7) in each trial group

Adolesc Health Med Ther